Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Horak, Peter; Heining, Christoph; Kreutzfeldt, Simon; Hutter, Barbara; Möck, Andreas; Hüllein, Jennifer; Fröhlich, Martina; Uhrig, Sebastian; Jahn, Arne; Rump, Andreas; Gieldon, Laura; Möhrmann, Lino; Hanf, Dorothea; Teleanu, Veronica; E. Heilig, Christoph; B. Lipka, Daniel; Allgäuer, Michael; Ruhnke, Leo; Laßmann, Andreas; Endris, Volker; Neumann, Olaf; Penzel, Roland; Beck, Katja; Richter, Daniela; Winter, Ulrike; Wolf, Stephan; Pfütze, Katrin; Geörg, Christina; Meißburger, Bettina; Buchhalter, Ivo; Augustin, Marinela; E. Aulitzky, Walter; Hohenberger, Peter; Kroiß, Matthias; Schirmacher, Peter; F. Schlenk, Richard; Keilholz, Ulrich; Klauschen, Frederick; Folprecht, Gunnar; Bauer, Sebastian; T. Siveke, Jens; Brandts, Christian; Kindler, Thomas; Boerries, Melanie; Lena Illert, Anna; von Bubnoff, Nikolas; J. Jost, Philipp; Spiekermann, Karsten; Bitzer, Michael; Schulze‐Osthoff, Klaus; von Kalle, Christof; Klink, Barbara; Brors, Benedikt; Stenzinger, Albrecht; Schröck, Evelin; Hübschmann, Daniel; Weichert, Wilko; Glimm, Hanno; Fröhling, Stefan

doi:10.1158/2159-8290.cd-21-0126

Public

Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

Published in Cancer Discovery • Jun 10, 2021

Authors:

Peter Horak

Christoph Heining

Simon Kreutzfeldt

Abstract

Abstract The clinical relevance of comprehensive molecular analysis in rare cancers is not established. We analyzed the molecular profiles and clinical outcomes of 1,310 patients (rare cancers, 75.5%) enrolled in a prospective observational study by the German Cancer Consortium that applies whole-ge...

Subject

Medicine

Clinical trial

Observational study

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!